

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSD:749US

10/039,171

List of Patents and Publications for Applicant's

Applicant

Robert Haley, *et al.*

Filing Date:

January 3, 2002

Group:

1645 1635

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
A <sub>2</sub>	C1	Abou-Donia <i>et al.</i> , "Increased neurotoxicity following concurrent exposure to pyridostigmine bromide, DEET, and chlorpyrifos," <i>Fund. Appl. Toxicol.</i> 34:201-222, 1996.
	C2	Adkins <i>et al.</i> , "Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes," <i>Am. J. Hum. Genet.</i> , 52:598-608, 1993.
	C3	Aldridge "An enzyme hydrolyzing diethyl p-nitrophenol phosphate (E600) and its identity with the A-esterase of mammalian sera," <i>Biochem. J.</i> , 53:117-124, 1953.
	C4	Betarbet <i>et al.</i> , "Chronic systemic pesticide exposure reproduces features of Parkinson's disease," <i>Nature Neuroscience</i> , 3:1301-1306, 2000.
	C5	Bharucha <i>et al.</i> , "Geographic distribution of motor neuron disease and correlation with possible etiologic factors," <i>Neurology</i> , 33:911-915, 1983.
	C6	Broomfield <i>et al.</i> , "Protection by butyrylcholinesterase against organophosphorus poisoning in nonhuman primates," <i>J. Pharm. Exper. Ther.</i> , 259:633-638, 1991.
	C7	Cao <i>et al.</i> , "Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q-->R genetic polymorphism," <i>J. Lipid Res.</i> , 40:133-139, 1999.
A <sub>4</sub>	C8	Caroscio <i>et al.</i> , "Amyotrophic lateral sclerosis: its natural history," <i>Neurol. Clin.</i> , 5:1-8, 1987.


25129131.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



TECH CENTER 1600/2900

OCT 23 2002

RECEIVED



Form PTO-1449 (modified)		Atty. Docket No. UTSD:749US	Serial No. 10/039,171
Office of Patents and Publications for Applicant's		Applicant Robert Haley, <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: January 3, 2002	Group: 1645 1671
(Use several sheets if necessary)			
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
P	C9	Checkoway <i>et al.</i> , "Genetic polymorphisms in Parkinson's disease," <i>Neurotoxicology</i> , 19:635-643, 1998.
	C10	Clendenning <i>et al.</i> , "Structural organization of the human <i>PON1</i> gene," <i>Genomics</i> , 35:586-589, 1996.
	C11	Costa and Manzo, "Biochemical markers of neurotoxicity: research strategies and epidemiological applications," <i>Toxicology Letters</i> , 77:137-144, 1995.
	C12	Costa <i>et al.</i> , "Serum paraoxonase and its influence on paraoxon and chlorpyrifos-oxon toxicity in rats," <i>Toxicol. Appl. Pharmacol.</i> , 103:66-76, 1990.
	C13	Costa <i>et al.</i> , "The role of paraoxonase (PON1) in the detoxication of organophosphates and its human polymorphism," <i>Chem. Biol. Interact.</i> , 119-120:429-438, 1999.
	C14	Davies <i>et al.</i> , "The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin," <i>Nat. Genet.</i> , 14:334-336, 1996.
	C15	Doctor <i>et al.</i> , "Cholinesterases as scavengers for organophosphorus compounds: protection of primate performance against soman toxicity," <i>Chem. Biol. Interact.</i> , 87:285-293, 1993.
	C16	Doctor <i>et al.</i> , "Enzymes as pretreatment drugs for organophosphate toxicity," <i>Neuroscience and Biobehavioral Reviews</i> , 15:123-128, 1991.
	C17	Dunn and Sidell, "Progress in medical defense against nerve agents," <i>JAMA</i> , 262:649-652, 1989.
	C18	Eckerson <i>et al.</i> , "The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts," <i>Am. J. Hum. Genet.</i> , 35:214-227, 1983.
	C19	Eckerson <i>et al.</i> , "The human serum paraoxonase/arylesterase polymorphism," <i>Am. J. Hum. Genet.</i> , 35:1126-1138, 1983.
	C20	Feingold <i>et al.</i> , "Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response," <i>Atherosclerosis</i> , 139:307-315, 1998.
	C21	Gan <i>et al.</i> , "Purification of human serum paraoxonase/arylesterase," <i>Drug Metab. Dispos.</i> , 19:100-106, 1991.
P	C22	Gray, "Design and structure-activity relationships of antidotes to organophosphorous anticholinesterase agents," <i>Drug Metabolism Reviews</i> , 15:557-589, 1984.

25129131.1

EXAMINER: D. [Signature]	DATE CONSIDERED: 7/27/01
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

RECEIVED

UTSD:749US

10/039,171

Applicant

Robert Haley, et al.

OCT 23 2002

Filing Date:

January 3, 2002

Group:

1645 1621

TECH CENTER 1600/2900

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
K~	C23	Haley and Kurt, "Self-reported exposure to neurotoxic chemical combinations in the Gulf War: a cross-sectional epidemiologic study," <i>JAMA</i> , 277:231-237, 1997.
	C24	Haley et al., "Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans," <i>Toxicol. Appl. Pharm.</i> , 157:227-233, 1999.
	C25	Hassett et al., "Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence," <i>Biochemistry</i> , 30:10141-10149, 1991.
	C26	Humbert et al., "The molecular basis of the human serum paraoxonase activity polymorphism," <i>Nature Genet.</i> , 3:73-76, 1993.
	C27	Husain et al., "A comparative study of delayed neurotoxicity in hens following repeated administration of organophosphorus compounds," <i>Indian J. Physiol. Pharmacol.</i> , 39:47-50, 1995.
	C28	Husain et al., "Delayed neurotoxic effect of sarin in mice after repeated inhalation exposure," <i>J. Appl. Toxicol.</i> , 13:143-145, 1993.
	C29	Ikeda et al., "Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus," <i>Metabolism</i> , 47:598-602, 1998.
	C30	Kao et al., "A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM," <i>J. Clin. Endocrinol. Metab.</i> , 83:2589-2592, 1998.
	C31	Keeler et al., "Pyridostigmine used as a nerve agent pretreatment under wartime conditions," <i>JAMA</i> , 266:693-695, 1991.
	C32	Konda and Yamamoto, "Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease," <i>Brain Research</i> , 806:271-273, 1998.
	C33	La Du et al., "Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals," <i>Drug Metab. Dispos.</i> , 29(4, Part 2): 566-569, 2001.
	C34	La Du, "Human serum paraoxonase/arylesterase," In: Kalow W, editor. <i>Pharmacogenetics of Drug Metabolism</i> . New York: Pergamon Press, Inc.; p. 51-91, 1992.
P~	C35	Langston, "Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate," <i>Ann. Neurol.</i> , 44 (Suppl 1):S45-S52, 1998.

25129131.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSD:749US

Serial No.

10/039,171

RECEIVED

OCT 23 2002

Applicant

Robert Haley, *et al.*

Filing Date:

January 3, 2002

Group:

1645 1671

TECH CENTER 1600/2900

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
P4	C36	Le Couteur <i>et al.</i> , "Pesticides and Parkinson's disease," <i>Biomed. Pharmacother.</i> , 53:122-130, 1999.
	C37	Li <i>et al.</i> , "Serum paraoxonase status: a major factor in determining resistance to organophosphates," <i>J. Toxicol. Environ. Health</i> , 40:337-346, 1993.
	C38	Li <i>et al.</i> , "Muscarinic receptor-mediated pyridostigmine-induced neuronal apoptosis," <i>Neurotoxicology</i> , 21:541-552, 2000.
	C39	Li <i>et al.</i> , "Paraopxonase protects against chlorpyrifos toxicity in mice," <i>Toxicology Letters</i> , 76:219-226, 1995.
	C40	Loewenstein-Lichtenstein <i>et al.</i> , "Genetic predisposition to adverse consequences of anti-cholinesterases in 'atypical' BChE carriers," <i>Nature Med.</i> , 1:1082-1085, 1995.
	C41	Lorentz <i>et al.</i> , "Arylesterase in serum: elaboration and clinical application of a fixed-incubation method," <i>Clin. Chem.</i> , 25/10:1714-1720, 1979.
	C42	Mackness <i>et al.</i> , "Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon," <i>Br. J. Pharmacol.</i> , 122:265-268, 1997.
	C43	Mackness <i>et al.</i> , "Human serum paraoxonase," <i>Gen. Pharmacol.</i> , 31(3):329-336, 1998.
	C44	Mackness <i>et al.</i> , "Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus," <i>Atherosclerosis</i> , 139:341-349, 1998.
	C45	McGeer <i>et al.</i> , "Familial nature and continuing morbidity of the amyotrophic lateral sclerosis-parkinsonism dementia complex of Guam," <i>Neurology</i> , 49:400-409, 1997.
	C46	McGuire <i>et al.</i> , "Occupational exposures and amyotrophic lateral sclerosis: a population-based case-control study," <i>Am. J. Epidemiol.</i> , 145:1076-1088, 1997.
	C47	Murata <i>et al.</i> , "Asymptomatic sequelae to acute sarin poisoning in the central and autonomic nervous system 6 months after the Tokyo subway attack," <i>J. Neurol.</i> , 244:601-606, 1997.
	C48	Odawara <i>et al.</i> , "Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus," <i>J. Clin. Endocrinol. Metab.</i> , 82:2257-2260, 1997.
P4	C49	Oyanagi and Wada, "Neuropathology of parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam: an update," <i>J. Neurol.</i> , 246 (Suppl 2):II/19-II/27, 1999.

25129131.1

EXAMINER:

D. L. H.

DATE CONSIDERED:

2/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

RECEIVED

UTSD:749US

10/039,171

OCT 23 2002

Applicant

Robert Haley, *et al.*

TECH CENTER 1600/2900

List of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

January 3, 2002

Group:

1645 1671

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Ab	C50	Pfohl <i>et al.</i> , "Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes," <i>Diabetes</i> , 48:623-627, 1999.
	C51	Playfer <i>et al.</i> , "Genetic polymorphism and interethnic variability of plasma paraoxonase activity," <i>J. Med. Genet.</i> , 13:337-342, 1976.
	C52	Poirier <i>et al.</i> , "Environment, genetics and idiopathic Parkinson's disease," <i>Can. J. Neurol. Sci.</i> , 18:70-76, 1991.
	C53	Primo-Parmo <i>et al.</i> , "The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family," <i>Genomics</i> , 33:498-507, 1996.
	C54	Sakai <i>et al.</i> , "Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus," <i>Intern. Med.</i> , 37:581-584, 1998.
	C55	Shih <i>et al.</i> , "Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis," <i>Nature</i> , 394:284-287, 1998.
	C56	Sidell, "Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates," <i>Clin. Toxicol.</i> , 7:1-17, 1974.
	C57	Sorenson <i>et al.</i> , "Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase," <i>Proc. Nat'l Acad. Sci. USA</i> , 92:7187-7191, 1995.
	C58	Sorenson <i>et al.</i> , "The genetic mapping and gene structure of mouse paraoxonase/arylesterase," <i>Genomics</i> , 30:431-438, 1995.
	C59	Tucker, "Evidence Iraq used chemical weapons during the 1991 Persian Gulf War," <i>The Nonproliferation Review</i> , Spring-Summer:114-122, 1997.
	C60	U.S. Senate Committee Report on Banking, Housing and Urban Affairs, United States Senate. U.S. chemical and biological warfare-related dual use exports to Iraq and their possible impact on the health consequences of the Persian Gulf War. Washington: U.S. Senate, 1994.
	C61	Yokoyama <i>et al.</i> , "A preliminary study of delayed vestibulocerebellar effects of Tokyo subway sarin poisoning in relation to gender difference: frequency analysis of postural sway," <i>J. Occup. Environ. Med.</i> , 40:17-21, 1998.
Ab	C62	Yokoyama <i>et al.</i> , "Chronic neurobehavioral and central and autonomic nervous system effects of Tokyo subway sarin poisoning," <i>J. Physiol. Paris</i> , 92:317-323, 1998.

25129131.1

EXAMINER:

P. H. H.

DATE CONSIDERED:

7/27/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)